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Abstract
Background: The number of human immunodeficiency virus (HIV)-related hospitalizations has decreased
worldwide in recent years, due to the availability of combined antiretroviral therapies (cART). The present
analysis aimed to analyse the economic, and clinical burden of HIV management, after the introduction of
systematic use of cART.
Methods: Data from HIV-infected patients, treated at Policlinico San Martino Hospital in Genova (Italy) were
retrospectively collected. A comparison between years 2009 and 2015 was performed. HIV-related admissions
were identified by using the Diagnosis-Related Group (DRG) codes. The resource consumption of outpatient
services was derived by using a modelling approach. Expenditure for drugs was also analysed, as aggregate
data.
Results: The number of HIV-infected patients was 898 in 2009 and 1006 in 2015. Overall, the virological success
rate improved from 2009 to 2015, as the percentage of patients with HIV-RNA < 50 copies/mL increased from
79 to 89% (P < 0.05). The average incidence of hospitalizations per-patient decreased from 0.30 in 2009, to 0.13
in 2015. Average expenditure per-patient decreased from €10,107 in 2009 to €9063 in 2015.
Conclusions: The present analysis confirmed the role of cART in controlling HIV viral load and, consequently,
in reducing hospitalizations, admissions to day-hospital and the use of outpatient services.
Clinical improvements and economic savings more than compensated the investments required to treat HIV-
infected patients with cART. Health Authorities should invest in modern cART supply and universal treatment,
to use at best the available resources and obtain a cost-effective improvement of health in people living with
HIV. Additional research, with the involvement of different centers and the use of patient-specific data, are
recommended to consolidate the findings of this analysis.
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Background
Recent published literature confirms that the number of
persons living with human immunodeficiency virus
(PLWHIV) is still rising [1]. There were approximately
36.7 million people worldwide living with human
immunodeficiency virus (HIV) or acquired immune defi-
ciency syndrome (AIDS) at the end of 2016 [1] and
130,000 living with HIV in Italy [2]. With the introduction
of combined antiretroviral therapy (cART), PLWHIV have
longer life expectancy and better quality of life than in the
past [3]. As a consequence, HIV care is now ranking as
one of the most expensive chronic diseases. Factors like: i)
growth of HIV prevalence [4] ii) increase of costs of newer
antiretrovirals [5]; iii) larger number of patients on
chronic therapy [4, 6]; iv) guidelines suggesting early
prescription of cART [7] and v) early access to treatment
as prevention, are the drivers of increasing expenditure in
HIV [8]. On the other side, several studies are showing
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that the number of HIV-related hospitalizations has
decreased in recent years, primarily because of the
availability of cART and, consequently, because of the
declining of the incidence of advanced HIV cases [9–11].
Although antiretroviral therapy is expensive, its cost-
effectiveness has been demonstrated in several analyses
[12–14]. Given the opposite trend in expenditure drivers
(drugs vs hospitalizations), detailed cost analyses are
crucial to measure economic cost-offset. Despite several
studies investigating the impact of the reduction in HIV/
AIDS-related morbidity and hospitalizations in the cART
era are available [8, 15, 16], breakdown of costs (i.e.
between hospital, pharmacological, outpatient, etc.) has
not been thoroughly characterized. This study is an
attempt to achieve a better understanding of the factors
affecting HIV-related hospitalizations and costs to optimize
the resource allocation.
Methods
Study objective
To analyse the economic, clinical burden changes in
HIV management, after the introduction of systematic
cART prescription in last years. A comparison of the
data observed in years 2009 and 2015 was performed.
Study design
This study was an observational, retrospective analysis
performed using Italian National Healthcare System
(NHS) data.
Data source
All data were collected on the MedInfo online plat-
form enclosed in Ligurian HIV Network; (www.reteli-
gureHIV.it). The Medinfo platform is an online
database for anonymous and automatic data collection
(laboratory test and clinical information) of
HIV-infected patients followed in the main hospitals
of Liguria (Italy) [17]. The platform is based on a web
service-oriented architecture that supports the auto-
matic and prospective transfer of laboratory data from
the electronic medical records to the Ligurian HIV
Network database [18]. The use of the Ligurian HIV
Network database was approved by the Ligurian Ethics
Committee (28 August 2013).
Inclusion criteria
The analysis was conducted on a cohort of patients
followed-up by the Infectious Disease Department of
Policlinico San Martino Hospital of Genova (Italy). Pa-
tients with confirmed HIV infection diagnosis were
identified as patients with at least one laboratory exam-
ination (CD4+ T cell count and HIV-RNA) per year.
Data collection
The following resource consumption data were collected
in the analysis: i) HIV-related hospitalizations / day
hospital (DH); ii) outpatient services, visits and exams;
iii) pharmacological treatment. HIV-related admissions
were identified using the Diagnosis-Related Group
(DRG) codes, 488 (HIV with extensive procedure), 489
(HIV with major related condition), 490 (HIV with or
without other related condition), based on the
International Classification of Diseases (ICD-9).
Hospitalization data were available in aggregate form.
However, for a subgroup of hospitalizations (43% of total
hospitalizations in 2009 - N = 115 of 265- and 91% in
2015 - N = 117 of 129 -) a patient database, reporting in-
dividual hospital admissions, was available. A detailed
analysis of such patient-level records was performed to
estimate: i) severity of the disease (indicating clinical
burden and considering patients’ co-morbidities and
other clinical information coded during the discharge);
ii) appropriateness (objective index taking into account
patient characteristics, type of service provided, length
of stay -LOS-, intensity of care, and level of physician in-
volvement [19]); iii) diagnosis; iv) in-hospital mortality.
A cost analysis was performed by comparing total costs
between 2009 and 2015. In absence of hospital
micro-costing data, hospital costs were estimating
through DRG tariffs. The Italian public hospitals are re-
munerated for their services through fixed DRG-specific
tariffs, which are set at national level and then (possibly)
adapted by the Regions. The national tariffs are good
proxies of standard costs sustained by the hospital (in-
cluding fixed costs, such as staff and overheads, build-
ings, and equipment, plus variable costs, such as, patient
care supplies, diagnostic and therapeutic supplies, etc.).
Therefore, hospitalizations costs were estimated using
the distribution of the three DRG of interest, in the sub-
group of hospitalizations for which all the information
was available (as per above, 43% in 2009 and 91% in
2015). The incidence values of the three DRG were then
multiplied by the respective Italian tariffs [20], to calcu-
late a weighted average hospital cost (see Additional file 1:
Table S1). Similarly, the resource consumption for DH
was modelled using a weighted average cost calculated
by using the latest national tariffs available (2013) [20]
and the number of admissions registered in Italy in years
2009 [21] and 2015 [22] (see Additional file 1: Table S1).
To estimate resource consumption for outpatient ser-
vices, it was assumed that patients with HIV-RNA <
50 copies/mL had 2.5 visits and exams per year (see
Additional file 1: Table S2) while patients with
HIV-RNA > 50 copies/mL had 4.5 visits and exams
per year, according to internal hospital monitoring
guidelines. The average number of visits was then
multiplied by the respective Italian tariff (code 89.7;
Taramasso et al. BMC Health Services Research  (2018) 18:691 Page 2 of 8
Additional file 1: Table S2) [23]. Since frequency of
monitoring could vary among hospitals, to adopted
clinical practice, two sensitivity analyses were run, by
assuming the same number of visits and exams for all
patients, regardless of viral load (Alternative Case A:
2.5 visits and exams per year; Alternative Case B: 4.5
visits and exams per year). Drug expenditure was ana-
lysed at an aggregate level. Prescriptions of treatments
associated with the following ATC (Anatomical
Therapeutic Chemical Classification System) codes
were considered: J05AE, protease inhibitors (PI);
J05AF, nucleoside and nucleotide reverse transcriptase
inhibitors (NRTI); J05AG, non-nucleoside reverse
transcriptase inhibitors (NNRTI); J05AR, fixed-dose
combination regimens (FDC); J05AX, other antivirals
(integrase, fusion and entry inhibitors). All data were
processed and analysed anonymously.
Statistical analysis
Standard descriptive statistics were used to analyse pa-
tients’ characteristics at baseline. All continuous vari-
ables were expressed as means (standard deviation) or
medians (interquartile range, IQR). Categorical data
were presented as percentages. For patient-level data, all
tests were two-sided and a P-value less than 0.05 was
considered statistically significant. T-test for continuous
variables, chi-square test for categorical variables, z-test
to compare two sample proportions for binary variables
were used to detect differences between the two groups
(year 2009 vs year 2015) and Mann-Whitney (rank-sum)
test to compare the medians of the two groups (year
2009 vs year 2015). For aggregate data no statistical test-
ing was conducted. Statistical analyses and calculations
were performed using both Microsoft Excel 2010
(Microsoft Corporation, Redmond, WA, USA) and
STATA software, release 13 (StataCorp. 2015. Stata Stat-
istical Software: Release 13. College Station, TX: Stata-
Corp LP).
Results
Patients’ characteristics
A total of N = 898 subjects were diagnosed with HIV in-
fection and included in the analysis in year 2009, and
N = 1006 in year 2015. The mean age among patients
undergoing at least one hospitalization was 47 years in
2009, and 49 years in 2015. The mean CD4+ T cell
count increased over the study period, from 501 cells/
mm3 (SD: 280.55) in 2009, to 637 cells/mm3 (SD:
337.94) in 2015 (P < 0.05). The percentage of patients
with optimal viral suppression (i.e. HIV-RNA
persistently< 50 copies/mL) grew from 79% in 2009 to
89% in 2015 (P < 0.05).
Hospitalizations (aggregate data analysis)
The average incidence of hospital admissions decreased
during the observed period, from 0.30 episodes
per-patient in year 2009, to 0.13 in year 2015 (P =
0.000). The average incidence of DH services decreased
during the observed period, from 0.10 episodes
per-patient in year 2009, to ≈0.00 in year 2015 (P =
0.000). The severity index of hospitalizations and DH in-
creased from 1.65 in year 2009 to 1.90 in year 2015 and
from 1.54 to 1.81, respectively.
Hospitalizations (disaggregate, per-patient level analysis)
To ensure that patients’ characteristics in years 2009
and 2015 were similar, statistical tests on available
data (N = 115 of 265 hospitalizations in 2009 and
N = 117 of 129 in 2015) were conducted.
The proportion of male patients was not statistically dif-
ferent between 2009 and 2015 (69% vs 73%, P = 0.604).
Similarly, the severity index of hospitalizations and the
proportion of non-Italian patients’ nationality were not
different (P = 0.243 and P = 0.245, respectively). Instead,
mean age was statistically different in 2009 and 2015 (45
vs 48 years, P = 0.009), but perhaps such difference would
be considered not relevant from an economic perspective
(i.e. not plausible that resource consumption would
change if age difference < 10 years, at least).
A trend of increasing proportion of hospitalizations
associated with the DRG code 489 (HIV with major re-
lated condition), was observed over time, but again, the
difference was not statistically significant when compar-
ing 2009 vs 2015 (P = 0.415; Fig. 1).
The proportion of appropriate hospitalizations numer-
ically increased from 46% in 2009 to 54% in 2015 (P =
0.465), while the rate of pre-planned hospitalizations de-
creased from 10% in 2009 to 2% in 2015 (P = 0.009). The
median LOS increased from 10 days (IQR: 5–16 days) in
2009 to 13 days (IQR: 7–19 days) in 2015 (P = 0.0331).
Aetiology leading to hospitalizations was categorized as
either directly or non-directly related to HIV. Hospitali-
zations associated with a primary diagnosis of HIV in-
creased over the study period from 84% (2009) to 95%
(2015, P = 0.008). A detailed analysis of secondary diag-
noses and procedures performed during hospitalizations
in the two study periods is shown in Figs. 2 and 3. In
this analysis an increase in cryptococcosis and encephal-
opathy secondary diagnosis was observed over time.
Moreover, procedures changed over the period of obser-
vation. In 2009 the main procedure was ultrasound diag-
nostic (abdominal and other side) while in 2015
procedures performed more frequently were non-venous
catheterization and blood transfusion which suggest a
greater severity of PLWHIV. Finally, a decreasing trend
of in-hospital mortality was observed (from 6.1% in 2009
to 5.1% in 2015; P = 0.751).
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Costs
Costs of ambulatory care, exams and drugs increased
from year 2009 to year 2015, whereas costs for hospitali-
zations and DH admissions decreased (Table 1). In the
Base-case analysis the mean cost per-patient decreased
from €10,107 in 2009 to €9063 in 2015, because of two
factors: i) reduction of the hospitalization rate, from 29.5
to 12.8%, respectively in 2009 and in 2015 (P = 0.000,
see Additional file 1: Table S1); ii) almost complete elim-
ination of the day hospital service (see Additional file 1:
Table S1). Figure 4 shows the distribution of pharma-
ceutical expenditure, in the Base-case analysis: an in-
crease in the expenditure for “other antivirals” and a
decrease in the expenditure for NRTI were basically ob-
served over time.
Sensitivity analyses on number of visits and exams con-
firmed robustness of Base-case analysis findings. In both
Alternative Cases (A and B), per patients costs remained
lower in the 2015 cohort compared to the 2009 cohort
(absolute difference:-€1030 in both cases). Such findings
confirm that monitoring costs are marginal, compared
with drug costs and hospitalization costs.
Discussion
Since 1996, the introduction of cART has improved life
expectancy and quality of life of PLWHIV [24]. Neverthe-
less, adoption of cART at lower CD4 +T lymphocyte
counts and with new and more expensive antiretrovirals
has triggered increased treatment costs [25–27]. In
addition, the use of highly active antiretroviral therapy
Fig. 2 Hospitalizations by secondary diagnosis (N = 115, Year 2009; N = 117, Year 2015). HIV = human immunodeficiency virus. Only diagnoses
with > 3% incidence were reported
Fig. 1 Distribution of the hospitalizations by DRG codes, (N = 115, Year 2009; N = 117, Year 2015)
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(HAART) has shown greater potential of preventing HIV
transmission [28]. In their study, Nosyk and Montaner
have shown that the cost-effectiveness of HAART roll-out
has been significantly underestimated, as economic ana-
lyses have thus far not considered the secondary benefits
of HAART, chief among them the impact of HAART on
HIV transmission.
The present analysis demonstrated that the increase in
the expenditure for cART (from €9.08 million in 2009,
to €9.10 million in 2015) was offset by a decrease in
other healthcare costs, such as hospitalizations and
day-hospital services. Moreover, the mean cost of cART
per-patient decreased from 2009 to 2015 (from €10,107
to €9063, respectively), despite a higher use of newer
Table 1 Results of the cost analysis
Results Total cohort analysis Per-patient analysis
Item of
expenditure
Cost in Year 2009, €
(N = 898a)
Cost in Year 2015, €
(N = 1006b)
Cost in Year 2009, €
(N = 898a)
Cost in Year 2015, €
(N = 1006b)
Base-case analysis Ambulatory care 51,175 54,770 57 54
Exams 233,903 250,334 260 249
Drugs 7,326,869 8,048,078 8159 8000
Hospitalizations 1,439,526 763,662 1603 759
Day-hospital access 24,924 540 28 1
Total per year 9,076,397 9,117,384 10,107 9063
Sensitivity analysis (Alternative Case A) Ambulatory care 46,382 51,960 52 52
Exams 211,995 237,491 236 236
Drugs 7,326,869 8,048,078 8159 8000
Hospitalizations 1,439,526 763,662 1603 759
Day-hospital access 24,924 540 28 1
Total per year 9,049,696 9,101,731 10,078 9047
Sensitivity analysis (Alternative Case B) Ambulatory care 83,487 93,528 93 93
Exams 381,592 427,485 425 425
Drugs 7,326,869 8159 1603 759
Hospitalizations 1,439,526 1603 28 1
Day-hospital access 24,924 28 8159 8000
Total per year 9,256,398 9,333,293 10,308 9278
aN = 782 patients (87%) with HIV-RNA < 50 copies/Ml; N = 116 patients (13%) with HIV-RNA > 50 copies/Ml
bN = 938 patients (93%) with HIV-RNA < 50 copies/Ml; N = 68 patients (7%) with HIV-RNA > 50 copies/Ml
Fig. 3 Hospitalizations by procedure (N = 115, Year 2009; N = 117, Year 2015). CT = tomography. Only procedures with > 5% incidence
were reported
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drugs, such as integrase strand inhibitor and single
tablet regimens.
Furthermore, this saving was accompanied by an im-
provement in immunological profile (higher mean CD4+
T lymphocytes counts) and HIV-RNA control (higher
proportion of patients with HIV-RNA < 50 copies/ml)
achieved during the study period. Indeed, an optimized
use of cART, combined with a stricter regional policy for
the containment of healthcare services [29], might have
determined the lower incidence of hospital admissions
observed in 2015 compared to 2009 and consequently a
decreasing of total expenditure per patient.
Importantly, although the severity of the patients rose
in 2015, the in-hospital mortality decreased from 6.1% in
2009 to 5.1% in 2015. Thus, not only the reduction of
the overall costs for patient in year 2015 was achieved,
but also all the patients related outcomes examined in
this study improved.
The improvement of clinical outcomes and the reduc-
tion in health care consumption more than compensated
the high expenditure required for cART.
In this analysis the benefit of the introduction of
direct-acting antiviral agents (DAA) is not yet evident.
In 2016 a new therapy era where HCV (hepatitis C
virus) can be cured has begun, with remarkable results
also in real-life settings and in special populations such
as HCV/HIV-co-infected patients [30–32].
Furthermore, the increasing in cryptococcosis and
encephalopathy, observed in our study, are a distinct-
ive condition of a late presentation of HIV [33–35].
After many years since the beginning of the HIV epi-
demics, still 15–38% of patients with HIV infection
continue to be diagnosed late. Late presenters demon-
strate a less favorable clinical outcome and they pro-
duce a considerable and unnecessary burden for the
healthcare system [36, 37].
This study has a few limitations, the most important
of which concerns the “mixed” approach followed for
the analysis. Aggregate data were partially used in the
present analysis, while a patient-based method should be
preferred, ideally. A comprehensive patient-based
method should have even allowed to conduct cost ana-
lyses stratified by immunological profile/virologic con-
trol or adjusted analyses. The availability of a limited
proportion of disaggregate, patient-level data for year
2009 could have influenced the significance of some re-
sults and their representativity. Furthermore, a general
change in health policies in last years, aimed at contain-
ing costs, especially during the period of economic crisis,
might have played a role in the changing of type and
number of hospitalizations that we found in our study.
Moreover, some costs were derived from assumptions
(i.e. ambulatory cares and hospitalizations/DH) and this
could have introduced some form of variability. Never-
theless, we do not believe these factors have substantially
biased the final direction of the results, which remain
valid. Finally, we believe that such results are representa-
tive of the Italian context but differences among systems
of reimbursement and tariffs applied by health care ser-
vices worldwide limit the applicability of the conclusions
obtained by this study to other international experiences.
Apart from the above-mentioned limitations, the results
of the present analysis provided a pharmacoeconomic
view on how cART use can impact both the clinical and
Fig. 4 Composition of drug expenditure among ATC code J05A products. J05A = Direct Acting Antivirals; PI = protease inhibitors; NRTI = nucleoside
and nucleotide reverse transcriptase inhibitors; NNRTI = non-nucleoside reverse transcriptase inhibitors; FDC = fixed-dose combination regimens
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economic burden of HIV. cART has transformed the
management of PLWHIV over the past quarter century.
However, the next years are crucial, the introduction of
new drugs (TAF, new single tablet regimen INSTI based,
protease inhibitor STR) will help to further improve
antiretroviral treatment.
Conclusion
The present analysis confirmed the role of cART in
controlling HIV in a more effective way and, conse-
quently, in reducing the burden of patients requiring
hospitalization, admission to day-hospital and outpatient
services. The gain in clinical outcomes and the reduction
in health care consumption more than compensate the
high expenditure required for cART. Health Authorities
should invest in modern cART supply and universal
treatment, to use at best the available resources and
obtain a cost-effective improvement of health in people
living with HIV. Additional research, with the involve-
ment of different centers and the use of patient-specific
data, are recommended to consolidate the findings of
this analysis.
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